What’s happening at InnoCore?

We are proud to announce the appointment of Hans de Backer as Chief Executive Officer. Hans joins the company with a proven track record as a strategy‑driven business leader, recognized for delivering sustainable growth, shepherding complex organizations, and building energized, high‑performance teams.

InnoCore Pharmaceuticals today initiated a new formulation development program focused on a specific small molecule drug substance, reinforcing its long-standing commitment to supporting its customers across a range of molecules.

InnoCore attended and presented at the PODD: Partnership Opportunities in Drug Delivery Conference, taking place between 27–28 October 2025 in Boston, MA.

InnoCore Pharmaceuticals today announced a project extension with an existing European biotech partner focused on developing a long-acting injectable protein formulation using its proprietary SynBiosys® technology.

InnoCore Pharmaceuticals today announced a new formulation development contract with a returning Top 10 global pharmaceutical company. The new agreement builds on the success of earlier collaborations and further strengthens the long-standing relationship between the two companies.

InnoCore launches its new website

InnoCore Pharmaceuticals today announced a new partnership with a U.S.-based biotechnology company developing next-generation GLP-1 therapies for obesity and metabolic diseases.

InnoCore Pharmaceuticals today announced a formulation development partnership with an undisclosed North American pharmaceutical company to advance a peptide therapeutic designed to support improved metabolic and glucose-control outcomes, potentially relevant to conditions such as Type 1 diabetes.

InnoCore Pharmaceuticals today announced a new formulation development project with a returning global pharmaceutical partner, building on a successful history of collaboration.